Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 4
1974 4
1975 17
1976 12
1977 5
1978 6
1979 2
1980 1
1981 13
1982 2
1983 4
1984 4
1985 1
1986 3
1987 4
1988 7
1989 5
1990 2
1991 4
1992 2
1993 4
1994 2
1995 3
1996 5
1997 3
1998 3
2000 1
2001 2
2003 1
2004 2
2005 2
2006 2
2007 2
2010 1
2012 5
2013 1
2014 1
2015 4
2016 3
2017 4
2018 4
2019 4
2020 6
2021 5
2022 3
2023 5
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Griffin M, et al. Circulation. 2020 Sep 15;142(11):1028-1039. doi: 10.1161/CIRCULATIONAHA.120.045691. Epub 2020 May 15. Circulation. 2020. PMID: 32410463 Free PMC article. Clinical Trial.
Fractional excretion of sodium increased significantly with empagliflozin monotherapy versus placebo (fractional excretion of sodium, 1.20.7% versus 0.70.4%; P=0.001), and there was a synergistic effect in combination with bumetanide (fractional excretion of sodium, 5.82.5 …
Fractional excretion of sodium increased significantly with empagliflozin monotherapy versus placebo (fractional excretion of sodium, 1.20.7 …
Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder.
Shaker E, El Agami O, Salamah A. Shaker E, et al. CNS Neurol Disord Drug Targets. 2024;23(4):536-542. doi: 10.2174/1871527322666230404114911. CNS Neurol Disord Drug Targets. 2024. PMID: 37021422 Clinical Trial.
Group 1 received Bumetanide, Group 2 received a placebo for 6 months. Follow-up by CARS rating scale was performed before and after 1, 3, and 6 months of treatment. RESULTS: The use of bumetanide in group 1 improved the core symptoms of ASD in a shorter time with mi …
Group 1 received Bumetanide, Group 2 received a placebo for 6 months. Follow-up by CARS rating scale was performed before and after 1 …
Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang WHW, Droogné W, Mullens W. Verbrugge FH, et al. Eur J Heart Fail. 2019 Nov;21(11):1415-1422. doi: 10.1002/ejhf.1478. Epub 2019 May 9. Eur J Heart Fail. 2019. PMID: 31074184 Free article. Clinical Trial.
Patients were randomised towards acetazolamide 250-500 mg daily plus bumetanide 1-2 mg bid vs. high-dose loop diuretics (bumetanide bid with daily dose twice the oral maintenance dose). ...Loop diuretic efficiency, defined as natriuresis corrected for loop diuretic …
Patients were randomised towards acetazolamide 250-500 mg daily plus bumetanide 1-2 mg bid vs. high-dose loop diuretics (bumetanid
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
Rao VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field MP, Wiederin DR, Butler J, Collins SP, Turner JM, Wilson FP, Inzucchi SE, Wilcox CS, Ellison DH, Testani JM. Rao VS, et al. J Am Soc Nephrol. 2024 Feb 1;35(2):189-201. doi: 10.1681/ASN.0000000000000269. Epub 2023 Dec 11. J Am Soc Nephrol. 2024. PMID: 38073038 Free PMC article. Clinical Trial.
Assessments were made with and without antagonism of sodium reabsorption through the loop using bumetanide. RESULTS: Empagliflozin resulted in a large decrease in sodium reabsorption in the PT (increase in FELi=7.5%10.6%, P = 0.001), with several observations suggesting in …
Assessments were made with and without antagonism of sodium reabsorption through the loop using bumetanide. RESULTS: Empagliflozin re …
Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder.
Juarez-Martinez EL, Sprengers JJ, Cristian G, Oranje B, van Andel DM, Avramiea AE, Simpraga S, Houtman SJ, Hardstone R, Gerver C, Jan van der Wilt G, Mansvelder HD, Eijkemans MJC, Linkenkaer-Hansen K, Bruining H. Juarez-Martinez EL, et al. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Mar;8(3):251-261. doi: 10.1016/j.bpsc.2021.08.009. Epub 2021 Sep 8. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023. PMID: 34506972 Free article. Clinical Trial.
BACKGROUND: Mechanism-based treatments such as bumetanide are being repurposed for autism spectrum disorder. We recently reported beneficial effects on repetitive behavioral symptoms that might be related to regulating excitation-inhibition (E/I) balance in the brain. Here …
BACKGROUND: Mechanism-based treatments such as bumetanide are being repurposed for autism spectrum disorder. We recently reported ben …
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.
Fuentes J, Parellada M, Georgoula C, Oliveira G, Marret S, Crutel V, Albarran C, Lambert E, Pénélaud PF, Ravel D, Ben Ari Y. Fuentes J, et al. Autism Res. 2023 Oct;16(10):2021-2034. doi: 10.1002/aur.3005. Epub 2023 Oct 4. Autism Res. 2023. PMID: 37794745 Clinical Trial.
In both studies, patients were randomized to receive bumetanide oral solution twice daily (BID) or placebo BID during a 6-month double-blind treatment period. ...In both studies, treatment-emergent adverse events that occurred more frequently with bumetanide than pl …
In both studies, patients were randomized to receive bumetanide oral solution twice daily (BID) or placebo BID during a 6-month doubl …
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Damier P, Degos B, Castelonovo G, Anheim M, Benatru I, Carrière N, Colin O, Defebvre L, Deverdal M, Eusebio A, Ferrier V, Giordana C, Houeto JL, Le Dily S, Mongin M, Thiriez C, Tranchant C, Ravel D, Corvol JC, Rascol O, Ben Ari Y. Damier P, et al. Mov Disord. 2024 Mar;39(3):618-622. doi: 10.1002/mds.29726. Epub 2024 Jan 30. Mov Disord. 2024. PMID: 38291616 Clinical Trial.
No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated. CONCLUSIONS: There was no evidence in this study that bumeta
No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. …
Clarifications regarding bumetanide for neonatal seizures.
Staley KJ. Staley KJ. Epilepsia. 2022 Jul;63(7):1863-1867. doi: 10.1111/epi.17278. Epub 2022 May 26. Epilepsia. 2022. PMID: 35524444 Free PMC article. Clinical Trial.
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity. Concerns regarding bumetanide as an adjunctive anticonvulsant are addressed here. An adequately …
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficac …
Clinical trial of bumetanide versus furosemide in patients with congestive heart failure.
Konecke LL. Konecke LL. J Clin Pharmacol. 1981 Nov-Dec;21(11):688-90. doi: 10.1002/j.1552-4604.1981.tb05684.x. J Clin Pharmacol. 1981. PMID: 7040496 Clinical Trial.
A clinical trial was conducted in open, randomized, parallel fashion to determine the effectiveness and safety of bumetanide compared with those of furosemide in 42 outpatients with edema due to congestive heart failure. ...Both diuretics proved equally effective in reduci …
A clinical trial was conducted in open, randomized, parallel fashion to determine the effectiveness and safety of bumetanide compared …
Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial.
Solis-Jimenez F, Perez-Navarro LM, Cabrera-Barron R, Chida-Romero JA, Martin-Alemañy G, Dehesa-López E, Madero M, Valdez-Ortiz R. Solis-Jimenez F, et al. BMC Nephrol. 2022 Sep 20;23(1):316. doi: 10.1186/s12882-022-02930-4. BMC Nephrol. 2022. PMID: 36127661 Free PMC article. Clinical Trial.
Patients were randomized into two groups: bumetanide plus chlorthalidone group (intervention) and the bumetanide plus placebo group (control) to evaluate differences in TBW, ECW and ECW/TBW between baseline and 30 Days of follow-up. ...CONCLUSION: In CKD stage 4-5 K …
Patients were randomized into two groups: bumetanide plus chlorthalidone group (intervention) and the bumetanide plus placebo …
173 results